https://economictimes.indiatimes.com/markets/stocks/news/hot-stocks-brokerage-views-on-mphasis-ashok-leyland-itc-and-piramal-pharma/articleshow/101036501.cms
0
0
54 words
0
Comments
Macquarie has downgraded Mphasis to underperform and lowered its target price, while maintaining an outperform rating on Mastek. Bofa Securities has a buy rating on Ashok Leyland, citing the company's good strategy and predicted margin improvement. Nomura ret…
You are the first to view
Create an account or login to join the discussion